ccdc80 Antibody

What is CCDC80 and what are its key biological functions?

CCDC80 is a secreted protein highly expressed in white adipose tissue that plays important roles in metabolic regulation through autocrine, paracrine, and endocrine mechanisms. It demonstrates biphasic expression during adipocyte differentiation, with high levels in both postconfluent preadipocytes and terminally differentiated adipocytes . CCDC80 has been identified as a critical mediator in several biological processes:

• Adipogenesis regulation through modulation of Wnt/β-catenin signaling and induction of C/EBPα and peroxisome proliferator-activated receptor γ

• Cell migration inhibition in melanoma cells

• Tumor suppression activity in gastric cancer models

• Immunomodulation within the tumor microenvironment, affecting macrophage polarization

The protein exists in multiple forms, including full-length (approximately 140 kDa) and processed fragments (95 kDa and 50 kDa) resulting from proteolytic cleavage events .

What are the recommended protocols for validating CCDC80 antibodies?

A thorough validation of CCDC80 antibodies should include:

• Positive and negative controls: Use tissues known to express CCDC80 (white adipose tissue, differentiated adipocytes) as positive controls . For negative controls, use tissues with minimal CCDC80 expression or knockdown cells with verified CCDC80 depletion through RNA interference .

• Western blot validation: When detecting CCDC80, researchers should look for multiple bands corresponding to the full-length protein (~140 kDa) and its processed fragments (~95 kDa and ~50 kDa) . The pattern may vary between cell types and differentiation states.

• Immunoprecipitation testing: Verify antibody specificity by immunoprecipitation followed by Western blot analysis. This approach can also help identify potential binding partners .

• Knockdown verification: Validate antibody specificity by comparing staining/detection in wildtype cells versus cells with CCDC80 knockdown using RNA interference .

• Cross-reactivity assessment: Test the antibody's reactivity across different species when relevant. The CCDC80 antibodies generated using peptides with 100% sequence homology between mouse and human can be effective for cross-species applications .

What are the optimal conditions for detecting endogenous CCDC80?

Detection of endogenous CCDC80 requires special consideration due to its secretory nature and post-translational modifications:

• Sample preparation for secreted protein analysis:

  • Collect conditioned media after 24-hour incubation in serum-free conditions

  • For 3T3-L1 cells, rinse twice with PBS before incubating in serum-free DMEM

  • Consider concentrating media samples for better detection

• Western blot recommendations:

  • Use 4-10% gradient SDS-PAGE for optimal separation of different molecular weight forms

  • Include protease inhibitors during sample preparation to prevent degradation

  • For the full protein detection spectrum, use antibodies targeting conserved regions

• Immunofluorescence detection:

  • Grow cells on appropriate substrates (e.g., Permanox slides)

  • Fix with 4% paraformaldehyde followed by permeabilization if detecting intracellular CCDC80

  • Block thoroughly to minimize background signal

• RT-qPCR detection:

  • Use validated primers specific to CCDC80 (e.g., forward: 5′-GATCCTGGAGCAGCCTCTGG-3′; reverse: 5′-ACATGGCTTCCAGCCTGACC-3′)

  • Include appropriate housekeeping genes like GAPDH for normalization

How can CCDC80 antibodies be used to study cancer progression and metastasis?

CCDC80 has emerging roles in regulating cancer cell migration and tumor progression. Researchers can employ CCDC80 antibodies to:

• Investigate the FAK/CCDC80/E-cadherin pathway:

  • Use co-immunoprecipitation with CCDC80 antibodies to identify interactions with FAK and other pathway components

  • Perform immunoblotting to monitor CCDC80 and E-cadherin expression levels following FAK knockdown or inhibition

  • Combine with migration assays to correlate CCDC80 expression with metastatic potential in various cancer models

• Study tumor microenvironment interactions:

  • Use immunohistochemistry with CCDC80 antibodies to assess distribution within tumor tissues

  • Correlate CCDC80 expression with immune cell infiltration markers

  • Implement dual staining approaches to identify cellular sources of CCDC80 within the tumor microenvironment

• Monitor treatment responses:

  • Track changes in CCDC80 expression following therapeutic interventions

  • Correlate changes in CCDC80 levels with clinical outcomes and treatment resistance

Research has demonstrated that CCDC80 inhibits B16F10 melanoma cell migration, and its expression inversely correlates with the metastatic potential of melanoma cells . Additionally, silencing CCDC80 in gastric cancer models inhibits malignant characteristics and tumor formation .

What approaches are effective for studying CCDC80's role in adipogenesis?

CCDC80 demonstrates a biphasic expression pattern during adipocyte differentiation. Researchers can use the following approaches:

• Temporal expression analysis:

  • Track CCDC80 protein levels at different stages of adipocyte differentiation using Western blot

  • Compare intracellular versus secreted forms throughout the differentiation process

  • Correlate with adipogenic markers (C/EBPα, PPARγ) to establish regulatory relationships

• Functional manipulation studies:

  • Use gain-of-function approaches through:

    • Adenoviral vector expression systems (e.g., pShuttle-CMV followed by recombination with pAdEasy-1)

    • Treatment with CCDC80-containing conditioned media

  • Use loss-of-function approaches through:

    • RNA interference with validated shRNA sequences targeting CCDC80

    • CRISPR-Cas9 mediated knockout

• Signaling pathway analysis:

  • Examine Wnt/β-catenin signaling activity in relation to CCDC80 levels

  • Monitor T-cell factor-mediated transcriptional activity using reporter assays

  • Assess downstream targets of CCDC80 through proteomic approaches coupled with immunoprecipitation

What are the challenges in detecting different proteolytic forms of CCDC80?

CCDC80 undergoes proteolytic processing that generates multiple protein fragments. Addressing these challenges requires:

• Antibody selection strategy:

  • Use antibodies targeting different epitopes to detect various CCDC80 fragments

  • The full-length protein (~140 kDa) and processed fragments (~95 kDa and ~50 kDa) have been observed in conditioned media

  • Generate or select antibodies against conserved regions to detect multiple forms

• Proteolytic processing investigation:

  • Include protease inhibitor cocktails to prevent artificial processing during sample preparation

  • Comparative analysis with and without protease inhibitors can help identify authentic processing events

  • Investigate cell surface-anchored or extracellular proteases involved in CCDC80 processing

• Experimental considerations:

  • Use appropriate gradient gels (4-10% SDS-PAGE) for optimal separation

  • Consider silver staining in parallel with immunoblotting for comprehensive protein detection

  • Employ immunoprecipitation with FLAG-tagged constructs for specific isolation of CCDC80 fragments

Research has shown that proteolytic processing of CCDC80 occurs through extracellular mechanisms, as addition of protease inhibitors to cell culture medium alters the pattern of secreted CCDC80 fragments .

How can CCDC80 antibodies be used to study immune infiltration in tumors?

Recent evidence indicates CCDC80 is a biomarker for immune infiltration in gastric cancer and influences macrophage polarization :

• Tumor microenvironment analysis:

  • Use immunohistochemistry with CCDC80 antibodies to map expression within tumor regions

  • Correlate CCDC80 expression with immune cell markers through multiplex immunostaining

  • Assess relationships between CCDC80 levels and immune infiltration scores derived from bioinformatic analyses

• Macrophage polarization studies:

  • Implement dual immunostaining for CCDC80 and macrophage markers (M1 versus M2)

  • Analyze the effect of CCDC80 silencing on macrophage polarization markers

  • Use flow cytometry with CCDC80 antibodies to phenotype tumor-associated macrophages

• Functional interrogation:

  • Perform co-culture experiments between cancer cells and macrophages with CCDC80 manipulation

  • Assess cytokine profiles in relation to CCDC80 expression levels

  • Investigate the mechanistic link between CCDC80 expression and immune cell recruitment/activation

Research has demonstrated that silencing CCDC80 inhibits M2 polarization and promotes M1 polarization in tumor tissues, suggesting a key role in modulating the tumor immune microenvironment .

What are the key considerations for generating anti-CCDC80 antibodies?

When developing antibodies against CCDC80, several factors should be considered:

• Epitope selection:

  • Target peptides with 100% sequence homology between species for cross-species applications

  • Previously successful epitopes include amino acids 148-165 and 672-685/671-684 (human/mouse)

  • Target conserved regions for detecting multiple species or functional domains for specific applications

• Production methodology:

  • Conjugate synthetic peptides to carriers like keyhole limpet hemocyanin

  • Implement standard immunization protocols (e.g., 90-day immunization schedule)

  • Purify antibodies using affinity columns against the immunizing peptide

• Validation requirements:

  • Confirm specificity using Western blot against endogenous and overexpressed CCDC80

  • Verify detection of secreted versus intracellular forms

  • Test functionality in multiple applications (Western blot, immunoprecipitation, immunofluorescence)

What controls should be included when using CCDC80 antibodies in experimental systems?

Proper experimental controls are essential for reliable results with CCDC80 antibodies:

• Expression controls:

  • Positive controls: Use differentiated adipocytes or tissues with known high CCDC80 expression

  • Negative controls: Use preconfluent preadipocytes or tissues with minimal CCDC80 expression

  • Genetic controls: Include CCDC80 knockdown or knockout samples using validated interference approaches

• Specificity controls:

  • Peptide competition assays to confirm antibody specificity

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls to identify any Fc receptor-mediated binding

• Expression manipulation controls:

  • Overexpression systems using adenoviral vectors encoding CCDC80

  • RNA interference using validated shRNA or siRNA sequences targeting CCDC80

  • Treatment with conditioned media containing CCDC80 (for secreted protein studies)

How can researchers optimize immunoprecipitation protocols for CCDC80?

Effective immunoprecipitation of CCDC80 requires attention to its secretory nature and multiple forms:

• Sample preparation:

  • For secreted CCDC80: Collect conditioned media after 24-hour incubation in serum-free conditions

  • For cellular CCDC80: Use gentle lysis buffers to preserve protein-protein interactions

  • Include protease inhibitors to prevent degradation during processing

• Immunoprecipitation strategy:

  • For tagged CCDC80: Use anti-FLAG resin for efficient capture of FLAG-tagged proteins

  • For endogenous CCDC80: Use affinity-purified antibodies coupled to protein A/G beads

  • Consider crosslinking antibodies to beads to prevent antibody contamination in eluted samples

• Elution considerations:

  • Use competitive elution with FLAG peptide for tagged proteins

  • For native protein complexes, consider gentler elution conditions to maintain interactions

  • For subsequent mass spectrometry analysis, avoid detergents that may interfere with peptide identification

What are the implications of CCDC80 as a biomarker in cancer prognosis?

Recent research highlights CCDC80's potential as a prognostic biomarker:

• Expression pattern analysis:

  • CCDC80 is significantly overexpressed in gastric cancer and correlates with immune invasion

  • Expression levels vary inversely with metastatic potential in melanoma models

  • Clinical data from Oncomine database shows decreased CCDC80 mRNA levels in melanoma patients compared to normal controls

• Correlation with genomic alterations:

  • High CCDC80 expression in gastric cancer correlates with mutations in CDH1, ACTRT1, GANAB, and CDH10 genes

  • These genetic associations may provide insight into the molecular contexts where CCDC80 functions

• Prognostic value assessment:

  • Analyze CCDC80 expression in relation to patient survival and treatment response

  • Evaluate potential as a predictive biomarker for immunotherapy response based on its role in immune cell regulation

How can CCDC80 antibodies be incorporated into multi-omics research approaches?

CCDC80 research benefits from integration with broader molecular profiling techniques:

• Proteomics integration:

  • Use CCDC80 immunoprecipitation coupled with mass spectrometry to identify protein interaction networks

  • Apply proximity labeling approaches (BioID, APEX) with CCDC80 antibodies to map spatial interactomes

  • Combine with phosphoproteomics to understand signaling cascades affected by CCDC80

• Transcriptomics correlation:

  • Correlate CCDC80 protein levels with gene expression signatures in various contexts

  • Use RNA-seq data from CCDC80 manipulation experiments to identify downstream regulatory networks

  • Apply single-cell approaches to understand cell-specific roles of CCDC80

• Spatial biology applications:

  • Implement multiplexed immunofluorescence to map CCDC80 distribution relative to cell types in tissues

  • Use imaging mass cytometry with CCDC80 antibodies to achieve higher multiplexing capabilities

  • Correlate spatial expression patterns with functional outcomes in disease models

The integration of CCDC80 antibody-based detection with these multi-omics approaches can provide comprehensive insights into its functional roles across diverse biological contexts.